| Autor: |
Bonaccorsi Riani, Eliano, Julliard, O, Ciccarelli, Olga, De Reyck, Chantal, Roggen, F, Hassoun, Ziad, Kabamba-Mukadi, Benoît, Sempoux, C, Lerut, Jan, 16th Annual Congress of the International-Liver-Transplantation-Society |
| Přispěvatelé: |
UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, UCL - (SLuc) Service de microbiologie, UCL - (SLuc) Service d'anatomie pathologique |
| Jazyk: |
angličtina |
| Rok vydání: |
2010 |
| Předmět: |
|
| Zdroj: |
Liver Transplantation, Vol. 16, no. Suppl 1, p. S145 (2010) |
| Popis: |
AIM: Compare the outcome of patients who underwent early (≤ 3 months ) and late (> 3 months after LT) re-LT in HCV(+) and HCV(-) patients (pts) in a single center retrospective study. METHODS AND MATERIAL: From February 1984 to July 2009, 895 LT were performed in 789 adults (≥ 16 yrs) in our center. Ninety-eight (12,4%) pts needed a second graft, 21 pts were HCV(+) and 77 pts were HCV(-). In the HCV(+) group, 12 pts underwent early and 9 pts late re-LT, in the HCV(-) pts, 41 pts and 36 pts needed early and late re-LT. Demographic data, clinical scores,second graft and patient survival of both groups were compared and analysed. RESULTS: HCV(+) pts were significantly older than HCV(-) pts (52,6± 9,5 vs 42,4±15,1 yrs) (p=0,004). Hepatocellular cancer was present in 20% of the HCV(+) pts and in 25% of the HCV(-) pts (ns). Mean time of late re-LT in HCV(+) and HCV(-) were 52,26±34,1 and 36,72±46,6 mo resp. (p=0,35). Mean follow-up was 69 mo (0,07 to 225). Main indications for early re-LT in HCV(+) and HCV(-) pts were graft dysfunction (7/12 and 23/41 resp.). Indications of late Re-LT in HCV(+) pts were HCV recurrence (7pts), ischemic type biliary lesion (ITBL) (1 pat) and HBV related cirrhosis (1 pat). ITBL was the main indication of late re-LT in the 19 HCV(-) pts, followed by chronic rejection in 10 pts. Actuarial 1-year patient survival rates after early re-LT for HCV(+) and HCV (-) pts. were 75% and 58% resp. (p=0,50). Actuarial and 1-year patient survival rates after late Re-OLT for HCV(+) and HCV(-) pts. were 89% and 83% resp. (ns). Actuarial and 5-year patient survival rates after early re-LT for HCV(+) and HCV (-) pts were 58% and 41% resp.(p=0,51). Actuarial and 5-year patient survival rates after late re-LT for HCV(+) and HCV(-) pts were 57% and 69% resp. (p=0,71). Six HCV(-) and only 1 pat. in the HCV(+) all needed a late second re-LT because ITBL. CONCLUSION: In these series re-LT in HCV(+) pts had comparable early and long term results to HCV(-) pts as well in case of early as late re-LT. Retransplantation remains a valuable treatment option in HCV(+) pts having both early graft dysfunction and allograft viral recurrence. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
